Top Abstract Purchase Related
Home
>
Node
>
Subnode

Biomarker development by cancer proteomics

Kondo, T.

Nihon Rinsho. Japanese Journal of Clinical Medicine 70(5): 754-758

2012

ISSN/ISBN: 0047-1852
PMID: 22619997
Document Number: 657136
Cancer is a genetically and clinically diverse disease, and biomarkers are required to optimize the therapeutic strategies. Proteome is a functional translation of genome, directly regulating cancer phenotypes. Biomarker studies have been conducted by the proteomic approach. By the proteomic approach, we developed a novel prognostic biomarker in gastrointestinal stromal tumor(GIST). In GIST, adjuvant imatinib mesylate after resection improved recurrence-free survival. A prognostic biomarker is required to select the patients for the treatment with imatinib mesylate. Proteomic approach using two-dimensional difference gel electrophoresis(2D-DIGE) identified pfetin as a biomarker for favorable prognosis. Multi-institutional validation study by immunohistochemistry established the prognostic values of pfetin in GIST. Pfetin will be applicable for a novel prognostic modality.

Document emailed within 1 workday
Secure & encrypted payments

Kondo, T. 2012: Proteomics for biomarker development toward personalized medicine Rinsho Byori. Japanese Journal of Clinical Pathology 60(7): 644-649
Lehmann, S.; Dupuy, A.; Peoc'h, K.; Roche, S.; Baudin, B.; Quillard, M.; Berger, F.; Briand, G.; Chwetzoff, S.; Dine, G.; Gonzalo, P.; Dastugue, B.; Sève, M.; Siest, G.; Beaudeux, J.-L. 2007: Present possibilities and future development of clinical proteomics Annales de Biologie Clinique 65(5): 463-471
Lucignani, G.; Bastianello, S. 2007: Pharmacological MRI: a biomarker in CNS drug discovery and development? Functional Neurology 22(2): 71-73
Nagasaka, T.; Mori, Y.; Umeda, Y.; Fujiwara, T. 2012: Biomarker for colorectal cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 70(5): 802-808
Presl, J.; Kučera, R.; Topolčan, O.; Novotný, Z.; Vrzalová, J.; Fuchsova, R.; Betincová, L.; Rokyta, Z. 2012: HE4 a biomarker of ovarian cancer Ceska Gynekologie 77(5): 445-449
Miyazaki, J.; Nishiyama, H. 2012: Biomarker for bladder cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(1): 48-53
Yucel, E.; Ilter, E.; Aksungar, F.B.; Celik, A.; Peker, B.H.; Serifsoy, E.; Bozkurt, S. 2017: HE4: really a novel biomarker for ovarian cancer? European Journal of Gynaecological Oncology 38(1): 59-64
Matsusaka, S. 2009: Biomarker for chemotherapy in patients with colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(1): 11-14
Fan, L.-q.; Li, Y.; Zhao, Q.; Tan, B.-b.; Ma, L.-g.; Liu, Y.; Wang, D. 2014: Comparative proteomics in gastric cancer cell line BGC823 after ZNF139 gene inhibited with RNA interference Hepato-Gastroenterology 61(134): 1822-1829
Chanukuppa, V.; Taware, R.; Chatterjee, T.; Sharma, S.; More, T.H.; Taunk, K.; Kumar, S.; Santra, M.K.; Rapole, S. 2018: Current Understanding of the Potential of Proteomics and Metabolomics Approaches in Cancer Chemoresistance: A Focus on Multiple Myeloma Current Topics in Medicinal Chemistry 18(30): 2584-2598
Ito, A.; Kawasaki, Y.; Kakoi, N.; Shimada, S.; Saito, S.; Arai, Y. 2016: Disialosyl globopentaosylceramide (DSGb5) as a biomarker of prostate cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 74(Suppl 3): 196-200
Hazama, S.; Maeda, K.; Oka, M. 2012: Epitope peptide vaccine with oncoantigen for cancer and its biomarker Nihon Rinsho. Japanese Journal of Clinical Medicine 70(12): 2189-2193
Kawamoto, H.; Fukuda, M. 2007: Present conditions and the prospects for biomarker measurement in breast cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 65(Suppl 6): 281-284
Kothandaraman, N.; Bajic, V.B.; Loganath, A.; Koh, S.; Ng, J.; Choolani, M.; Razvi, K. 2004: Early detection of epithelial ovarian cancer using a proteomics-based protein-profiling approach combined with a novel selection strategy Annals of the Academy of Medicine Singapore 33(5 Suppl): S59-S60
Gilbert, F.; Walop, W.; Chan, J.S.; Benjannet, S.; Seidah, N.G.; Spitzer, W.O.; Chrétien, M. 1987: The role of the NH2-terminal portion of pro-opiomelanocortin as a biomarker for human lung cancer Clinical and Investigative Medicine. Medecine Clinique et Experimentale 10(5): 372-376
Terakawa, H.; Oyama, K.; Watanabe, T.; Tsukada, T.; Okamoto, K.; Kinoshita, J.; Furukawa, H.; Makino, I.; Nakamura, K.; Hayashi, H.; Inokuchi, M.; Nakagawara, H.; Miyashita, T.; Tajima, H.; Takamura, H.; Ninomiya, I.; Kitagawa, H.; Fushida, S.; Fujimura, T.; Ohta, T. 2014: A case of advanced gastric cancer in which the serum HER2-ECD level could be used as a biomarker Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(4): 491-493
Zhang, Z.; Hao, H.; Zhang, C.-j.; Yang, X.-y.; He, Q.; Lin, J. 2012: Evaluation of novel gene UCA1 as a tumor biomarker for the detection of bladder cancer Zhonghua Yi Xue Za Zhi 92(6): 384-387
Burton, C.; Ma, Y. 2019: Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges Current Medicinal Chemistry 26(1): 5-28
Nikolic, A.; Vlajnic, M.; Ristanovic, M.; Petrovic, J.; Dimitrijevic, I.; Krivokapic, Z.; Radojkovic, D. 2017: Cell-free DNA as biomarker and source for mutation detection in primary colorectal cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 22(1): 178-183
Verderio, P.; Mangia, A.; Orlando, C.; Belfiglio, M.; Marchetti, A.; Bertario, L.; Chiappetta, G.; Gion, M.; Tonini, G.Paolo.; Podo, F.; Vocaturo, A.; Silvestrini, R.; Lombardo, C.; Paradiso, A. 2010: Research trends for early cancer biomarker detection in Italy: an integrated program in oncology (PIO) survey Tumori 96(5): 721-725